STOCK TITAN
  1. Home
  2. Sec-filings
  3. FBRX
  4. [Form 4] Forte Biosciences, Inc. Insider Trading Activity

Forte Biosciences (FBRX) CFO nets shares from RSU vesting and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Forte Biosciences, Inc. chief financial officer Riley Antony reported compensation-related stock activity. On July 1, 2026, he exercised 375 Restricted Stock Units (RSUs), receiving the same number of Common Stock shares. To cover tax obligations, 134 Common Stock shares were disposed of via share withholding, not an open-market sale.

Following these transactions, Antony holds 42,734 Common Stock shares directly, according to the filing, which includes 377 shares acquired under the 2017 Employee Stock Purchase Plan. The activity reflects routine RSU vesting and tax withholding rather than discretionary buying or selling in the market.

Positive

  • None.

Negative

  • None.
Insider Riley Antony A
Role CHIEF FINANCIAL OFFICER
Type Security Shares Price Value
Exercise Restricted Stock Units 375 $0.00 --
Exercise Common Stock 375 $0.00 --
Tax Withholding Common Stock 134 $21.32 $3K
Holdings After Transaction: Restricted Stock Units — 750 shares (Direct, null); Common Stock — 42,734 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. Includes 377 shares of Common Stock acquired July 1, 2026 under the Issuer's 2017 Employee Stock Purchase Plan. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
RSUs exercised 375 shares RSUs converted to Common Stock on July 1, 2026
Shares withheld for taxes 134 shares Tax-withholding disposition of Common Stock on July 1, 2026
Post-transaction holdings 42,734 shares Common Stock directly owned after reported transactions
ESPP acquisition 377 shares Common Stock acquired under 2017 Employee Stock Purchase Plan on July 1, 2026
RSU vesting schedule 1/16 per quarter RSUs vest each Quarterly Vesting Date starting February 1, 2023
Restricted Stock Units financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2017 Employee Stock Purchase Plan financial
"Includes 377 shares of Common Stock acquired July 1, 2026 under the Issuer's 2017 Employee Stock Purchase Plan."
2021 Equity Incentive Plan financial
"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date..."
Quarterly Vesting Date financial
"For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Riley Antony A
(Last)(First)(Middle)
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BLDG 6
(Street)
DALLAS TEXAS 75247
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF FINANCIAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M375A(1)42,734(2)D
Common Stock07/01/2026F134D$21.3242,600D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)07/01/2026M375 (3) (3)Common Stock375$0750D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. Includes 377 shares of Common Stock acquired July 1, 2026 under the Issuer's 2017 Employee Stock Purchase Plan.
3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR